Shaanxi Key Laboratory of Degradable Biomedical Materials, School of Chemical Engineering, Northwest University, Xi'an 710069, China.
Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Engineering, Northwest University, Xi'an 710069, China.
J Agric Food Chem. 2020 May 6;68(18):5107-5117. doi: 10.1021/acs.jafc.0c00605. Epub 2020 Apr 27.
In this study, we aimed to investigate the influence of ginsenoside Rg5 (Rg5) on gut microbiota in diabetic db/db mice. Our data indicated that Rg5 not only improved the symptoms of hyperglycemia, repaired intestinal barrier function, and relieved metabolic endotoxemia-related inflammation but also reversed gut microbiota dysbiosis in the colon with significantly decreased ratios. More importantly, the effects of Rg5 were further confirmed by partial changes in the gut microbiota induced by broad-spectrum antibiotics. These findings indicated that Rg5 dramatically decreased the abundance of and at the phylum level and increased the abundance of and in diabetic db/db mice. Altogether, our findings, for the first time, demonstrate that Rg5 may be used as a beneficial probiotic agent that reverses gut microbiota dysbiosis and diabetes-associated metabolic disorders in the context of type 2 diabetes mellitus.
在这项研究中，我们旨在探讨人参皂苷 Rg5（Rg5）对糖尿病 db/db 小鼠肠道微生物群的影响。我们的数据表明，Rg5 不仅改善了高血糖症状，修复了肠道屏障功能，缓解了代谢性内毒素血症相关炎症，还逆转了结肠的肠道微生物群失调，使 比例显著降低。更重要的是，广谱抗生素引起的肠道微生物群的部分变化进一步证实了 Rg5 的作用。这些发现表明，Rg5 显著降低了糖尿病 db/db 小鼠肠道微生物群在门水平上的 和 的丰度，增加了 和 的丰度。总的来说，我们的研究结果首次表明，Rg5 可能作为一种有益的益生菌制剂，在 2 型糖尿病的背景下逆转肠道微生物群失调和与糖尿病相关的代谢紊乱。
